About: Postexposure Protection of Guinea Pigs against a Lethal Ebola Virus Challenge Is Conferred by RNA Interference

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Postexposure Protection of Guinea Pigs against a Lethal Ebola Virus Challenge Is Conferred by RNA Interference Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Postexposure Protection of Guinea Pigs against a Lethal Ebola Virus Challenge Is Conferred by RNA Interference
Creator	Jahrling, Peter Hensley, Lisa Daddario-Dicaprio, Kathleen Fritz, Elizabeth Geisbert, Joan Geisbert, Thomas Judge, Adam Lee, Amy Maclachlan, Ian Jeffs, Lloyd Kagan, Elliott Mcclintock, Kevin Phelps, Janet Yu, Erik
topic	covid:1d4e0da51363ff2dce0803333aa67135451e3c0f#this
Source	Medline; PMC
abstract	BackgroundEbola virus (EBOV) infection causes a frequently fatal hemorrhagic fever (HF) that is refractory to treatment with currently available antiviral therapeutics. RNA interference represents a powerful, naturally occurring biological strategy for the inhibition of gene expression and has demonstrated utility in the inhibition of viral replication. Here, we describe the development of a potential therapy for EBOV infection that is based on small interfering RNAs (siRNAs) MethodsFour siRNAs targeting the polymerase (L) gene of the Zaire species of EBOV (ZEBOV) were either complexed with polyethylenimine (PEI) or formulated in stable nucleic acid–lipid particles (SNALPs). Guinea pigs were treated with these siRNAs either before or after lethal ZEBOV challenge ResultsTreatment of guinea pigs with a pool of the L gene–specific siRNAs delivered by PEI polyplexes reduced plasma viremia levels and partially protected the animals from death when administered shortly before the ZEBOV challenge. Evaluation of the same pool of siRNAs delivered using SNALPs proved that this system was more efficacious, as it completely protected guinea pigs against viremia and death when administered shortly after the ZEBOV challenge. Additional experiments showed that 1 of the 4 siRNAs alone could completely protect guinea pigs from a lethal ZEBOV challenge ConclusionsFurther development of this technology has the potential to yield effective treatments for EBOV HF as well as for diseases caused by other agents that are considered to be biological threats
has issue date	2006-06-15(xsd:dateTime)
bibo:doi	10.1086/504267
bibo:pmid	16703508
has license	no-cc
sha1sum (hex)	1d4e0da51363ff2dce0803333aa67135451e3c0f
schema:url	https://doi.org/10.1086/504267
resource representing a document's title	Postexposure Protection of Guinea Pigs against a Lethal Ebola Virus Challenge Is Conferred by RNA Interference
has PubMed Central identifier	PMC7110204
has PubMed identifier	16703508
schema:publication	J Infect Dis
resource representing a document's body	covid:1d4e0da51363ff2dce0803333aa67135451e3c0f#body_text
is http://vocab.deri.ie/void#inDataset of	proxy:http/ns.inria.fr/covid19/1d4e0da51363ff2dce0803333aa67135451e3c0f
is schema:about of	named entity 'CHALLENGE' named entity 'infection' named entity 'describe' named entity 'RNA interference' named entity 'Virus' named entity 'INHIBITION' named entity 'TREATMENT' named entity 'AVAILABLE' named entity 'CURRENTLY' named entity 'FATAL' named entity 'POTENTIAL' named entity 'EBOLA VIRUS' named entity 'RNA INTERFERENCE' named entity 'SMALL INTERFERING RNAS' named entity 'EBOLA VIRUS' named entity 'BIOLOGICAL' named entity 'REFRACTORY' named entity 'CAUSES' named entity 'UTILITY' named entity 'DEMONSTRATED' named entity 'DEVELOPMENT' covid:arg/1d4e0da51363ff2dce0803333aa67135451e3c0f named entity 'RNA INTERFERENCE' named entity 'NATURALLY OCCURRING' named entity 'ANTIVIRAL' named entity 'BASED' named entity 'THERAPEUTICS' named entity 'THERAPY' named entity 'INFECTION' named entity 'POWERFUL' named entity 'DESCRIBE' named entity 'HEMORRHAGIC FEVER' named entity 'STRATEGY' named entity 'HERE' named entity 'INHIBITION OF VIRAL REPLICATION' named entity 'GENE EXPRESSION' named entity 'FREQUENTLY' named entity 'GUINEA PIGS' named entity 'LETHAL' named entity 'PROTECTION' named entity 'EBOV' named entity 'based' named entity 'potential' named entity 'hemorrhagic fever' named entity 'RNA interference' named entity 'Ebola' named entity 'virus' named entity 'infection' named entity 'naturally occurring' named entity 'therapy' named entity 'siRNA' named entity 'guinea pigs' named entity 'siRNA' named entity 'cytokines' named entity 'HIV' named entity 'transfection' named entity 'polymers' named entity 'immune response' named entity 'siRNA' named entity 'immunostimulatory' named entity 'siRNA' named entity 'RNAi' named entity 'guinea pigs' named entity 'siRNAs' named entity 'ZEBOV' named entity 'vaccines'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software